VTIX Virtuix, Inc.
Price Chart
Executive Summary
Virtuix announced that Rutgers University has deployed its Omni One platform for research into AI-assisted neurodivergent therapy and behavioral analytics. This is a non-revenue academic collaboration that validates the platform's potential in healthcare but has no immediate financial impact.
Actionable Insight
This is a non-revenue academic pilot with no disclosed financial terms. Monitor for future healthcare contracts or revenue-generating partnerships, but the filing provides no catalyst for near-term stock movement.
Key Facts
- Rutgers University deployed Omni One at WINLAB for research on AI-assisted neurodivergent therapy and behavioral analytics.
- The collaboration focuses on autism therapy for children, evaluating attention, movement patterns, and response timing.
- No financial terms, revenue, or material obligations were disclosed.
- Virtuix's primary focus remains consumer entertainment and defense; healthcare is an exploratory vertical.
- The global ASD treatment market is projected to grow from ~$9.2B in 2026 to >$18B by 2034 (9% CAGR), per Fortune Business Insights.
Financial Impact
No revenue or financial commitment disclosed; immaterial to near-term financials.
Risk Factors
- Academic collaborations rarely convert to material revenue without multi-year validation cycles.
- Virtuix's stock has shown high volatility and negative historical drift (avg T+20 alpha -15.79% on prior reports).
- No timeline or milestones for commercial healthcare product were provided.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298589 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 20, 2026
1d ago
|
Press Release
| $3.39 awaiting T+5 | awaiting T+5 | — | $3.33 (−1.77%) |
|
May 14, 2026
7d ago
|
EFFECT
| — | awaiting T+5 | — | — |
|
May 5, 2026
16d ago
|
Press Release
| $3.85 $4.08 | ▲ +5.97% | ▲ +3.99% | $3.33 (−13.51%) |
|
Apr 2, 2026
7w ago
|
8-K
| $6.03 $6.12 | ▼ −1.49% | ▲ +2.13% | $3.33 (+44.78%) |
|
Mar 5, 2026
11w ago
|
Press Release
| $6.82 $6.87 | ▲ +0.73% | ▲ +2.97% | $3.33 (−51.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access